Re: Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/formoterol (18/12 mu g once daily via a Discair inhaler), tiotropium alone (18 mu g by Handihaler) or combined with formoterol (12 mu g twice daily by Aerolizer) in adults with

Full Terms & Conditions of access and use can be found at

https://www.tandfonline.com/action/journalInformation?journalCode=icmo20

Current Medical Research and Opinion

ISSN: 0300-7995 (Print) 1473-4877 (Online) Journal homepage: https://www.tandfonline.com/loi/icmo20

Re: Yildiz BP, Bayraktaroglu M, Gunen H.

Bronchodilator efficacy of tiotropium/formoterol

(18/12 

µ

g once daily via a Discair inhaler),

tiotropium alone (18 

µ

g by Handihaler) or

combined with formoterol (12 

µ

g twice daily by

Aerolizer) in adults with moderate-to-severe stable

COPD. Curr Med Res Opin. 2019;35(12):2187–2196

Serdar Kalemci, Aydin Sarihan, Ahmet Bülent Kargı, Abdullah Şimşek & Arife

Zeybek

To cite this article: Serdar Kalemci, Aydin Sarihan, Ahmet Bülent Kargı, Abdullah Şimşek & Arife Zeybek (2020) Re: Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/ formoterol (18/12 µg once daily via a Discair inhaler), tiotropium alone (18 µg by Handihaler) or combined with formoterol (12 µg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD. Curr Med Res Opin. 2019;35(12):2187–2196 , Current Medical Research and Opinion, 36:6, 1059-1059, DOI: 10.1080/03007995.2020.1754184

To link to this article: https://doi.org/10.1080/03007995.2020.1754184

Published online: 29 Apr 2020. _{Submit your article to this journal}

Article views: 385 _{View related articles}

View Crossmark data

CMRO

6

~ Taylor&FrancisGroup -· ~ • •~· ~ ·- .•••• ~ ~ - - • - : ; : -•- R ~ - - R .... ·--

--

-

--

---..

__

_

______

..

8"

ılıl

r!ı

8"

®

8"

LETTER TO THE EDITOR

Re: Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/

formoterol (18/12

lg once daily via a Discair inhaler), tiotropium alone (18 lg by

Handihaler) or combined with formoterol (12

lg twice daily by Aerolizer) in

adults with moderate-to-severe stable COPD. Curr Med Res Opin.

2019;35(12):2187

–2196

Dear Editor,

We read with interest the article recently published by Yildiz et al. entitled“Bronchodilator efficacy of tiotropium/formoterol (18/12mg once daily via a Discair inhaler) [TIO/FORMfixed

group], tiotropium alone (18mg by Handihaler) [TIOmonogroup]

or combined with formoterol (12mg twice daily by Aerolizer) [TIO/FORMbid group] in adults with moderate-to-severe stable

COPD”1. In the study, it was shown that a single daily dose of TIO/FORMfixed is as effective as a combination of TIO/FORMbid

and TIOmono, and more effective than TIOmono.

In the study, we saw that 12 patients in the TIOmono

group, 7 patients in the TIO/FORMbidgroup and 9 patients in

the TIO/FORMfixed group had had exacerbations in the last

year. In addition, the mean CAT score was 18.3 in the TIOmono group, 17.1 in the TIO/FORMbid group and 17.1 in

the TIO/FORMfixedgroup. When compared with other groups,

we saw that patients in the TIOmonogroup had more

exacer-bations and were more symptomatic in the last year. In patients with COPD, as the number of exacerbations and symptoms increase, the severity of the disease increases and response to inhaler therapy gets worse2_{. We believe that this}

condition may affect the results of the study.

Transparency

Declaration of funding

No funding to disclose.

Declaration of financial/other relationships

No potential conflict of interest was reported by the authors.

Acknowledgements

None reported.

ORCID

Serdar Kalemci http://orcid.org/0000-0002-5246-972X

Aydin Sarihan http://orcid.org/0000-0002-7489-0734

Abdullah S¸ims¸ek http://orcid.org/0000-0003-0588-3888

Arife Zeybek http://orcid.org/0000-0003-3656-9947

References

[1] Yildiz BP, Bayraktaroglu M, Gunen H. Bronchodilator efficacy of tiotropium/formoterol (18/12 mg once daily via a Discair inhaler), tiotropium alone (18 mg by Handihaler) or combined with formoterol (12mg twice daily by Aerolizer) in adults with moderate-to-severe stable COPD. Curr Med Res Opin. 2019; 35(12):1–10.

[2] L
opez-Campos JL, Gallego EQ, Hern
andez LC. Status of and strat-egies for improving adherence to COPD treatment. COPD. 2019; 14:1503–1515.

Serdar Kalemci Medical Park Gebze Hospital, Gebze, Turkey

Aydin Sarihan Manisa Sehir Hastanesi, Manisa City Hospital, Manisa, Turkey

aydinsarihan@yahoo.com

Ahmet B€ulent Kargı Medical Park Gebze Hospital, Gebze, Turkey

Abdullah S¸ims¸ek Bursa Chest Disease Hospital, Yıldırım, Turkey

Arife Zeybek Mugla Sıtkı Koc¸man €Universitesi, Mugla, Turkey

Received 3 December 2019; revised 14 February 2020; accepted 4 April 2020

ß 2020 Informa UK Limited, trading as Taylor & Francis Group CURRENT MEDICAL RESEARCH AND OPINION

2020, VOL. 36, NO. 6, 1059

https://doi.org/10.1080/03007995.2020.1754184 Article ST-0679.R1/1754184

All rights reserved: reproduction in whole or part not permitted

I

_e

e

~